My view is always to partner with a well established distributor they could provide upfront and milestone payments to fund the DurAVR and delivery products to commercialisation. In return, the partner got exclusive rights and guaranteed margin say 15% of sales over a fixed term with option to renew.
I see selling the company short with the unmatched technology and the groundbreaking tissue science product having even greater potential for many more emerging new products potential. I see ADAPT could be worth much more than DurAVR and that was the tissue science got me invested over 3 years ago.
if SIO, Mercer and the top shareholders share the same opinion, we could well be another CSL in the making.
DYOR!
CEO presentation - one of the best I have seen., page-49
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M | |||
| Open | High | Low | Value | Volume |
| $18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 247 | 2 |
View Market Depth
| Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |